Mind Medicine (MindMed) Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Barrow
- Full Time Employees
- 74
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1055 West Hastings Street Vancouver BC Canada V6E 2E9
- IPO Date
- Nov 15, 2016
- CIK
- 0001813814
- Website
- mindmed.co
- Similar Companies
- Business
- Mind Medicine (MindMed) Inc. (MNMD) is a late-stage clinical biopharmaceutical company that develops novel product candidates to treat brain health disorders, including anxiety, depression, and autism spectrum disorder; its pipeline targets neurotransmitter pathways with and without acute perceptual effects, featuring pharmaceutically optimized formulations derived from psychedelics and empathogens. The company offers MM120 ODT, a proprietary lysergide D-tartrate (LSD) orally disintegrating tablet incorporating Catalent’s Zydis fast-dissolve technology for faster absorption and improved bioavailability, in Phase 3 trials for generalized anxiety disorder (GAD) across Voyage and Panorama studies and for major depressive disorder (MDD) in Emerge and planned Ascend studies; MM402, the R(-)-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA) with pro-social effects and reduced stimulant activity, advances to a Phase 2a study in autism spectrum disorder (ASD) in the fourth quarter of 2025 following Phase 1 completion. Founded in 2019 and headquartered at One World Trade Center in New York, NY, with operations extending to Canada, MindMed focuses on psychiatry and neurology patient populations in the United States and Europe. Recent developments include publication of Phase 2b GAD results in the Journal of the American Medical Association demonstrating significant efficacy of MM120 100 µg, FDA Breakthrough Therapy Designation for MM120 in GAD in March 2024, accelerated topline data expectations for Emerge to mid-2026, and completion of a $258.9 million public offering in October 2025 yielding $242.8 million in net proceeds to fund operations into 2028.
Short Interest in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Grows By 19.4%
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Robert Barrow Sells 25,791 Shares of Stock
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of “Buy” from Analysts
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
MindMed Announces New Employee Inducement Grant
MindMed Announces New Employee Inducement Grants
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of “Buy” from Analysts
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
MindMed Reports Q3 2025 Financial Results and Business Updates
MindMed to Participate in Upcoming Investor Conferences
MindMed Announces New Employee Inducement Grant
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
MindMed Announces New Employee Inducement Grant
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Mind Medicine initiated with an Outperform at LifeSci Capital